SCHEMBL4866094

SCHEMBL4866094

O=c1[nH]cnc2cc(NCC3(c4ccc(Cl)cc4)CCNCC3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
PARP1 P09874 3/20 0.41
ROCK2 O75116 1/20 0.41
TEK Q02763 9/20 0.39
KDR P35968 6/20 0.39
IP6K1 Q92551 2/20 0.39
MCHR1 Q99705 1/20 0.38
EPHB4 P54760 6/20 0.38
CHEK1 O14757 1/20 0.38
PIM1 P11309 1/20 0.38
RPS6KA3 P51812 1/20 0.38
EGFR P00533 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
FGFR1 P11362 1/20 0.37
FLT1 P17948 1/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
CTSD P07339 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4874988 0.80 ALDH1A1 (0.50) ALDH1A1PARP1TEKKDRIP6K1
SCHEMBL14003520 0.79 TEK (0.51) ALDH1A1ROCK2TEKKDREPHB4
SCHEMBL8213573 0.72 TEK (0.55) ALDH1A1ROCK2TEKKDREPHB4
SCHEMBL4876792 0.72 ALDH1A1 (0.50) ALDH1A1PARP1TEKKDRIP6K1
SCHEMBL4876787 0.72 ALDH1A1 (0.50) ALDH1A1PARP1TEKKDRIP6K1
SCHEMBL14003524 0.71 PIK3CD (0.55) ALDH1A1PARP1TEKKDRIP6K1
Hydrochloric Acid SCHEMBL4869739 0.71 ALDH1A1 (0.49) ALDH1A1PARP1TEKKDRIP6K1
SCHEMBL4869946 0.71 PIK3CD (0.55) ALDH1A1PARP1IP6K1CHEK1PIM1
Hydrochloric Acid SCHEMBL4869731 0.71 ALDH1A1 (0.49) ALDH1A1PARP1TEKKDRIP6K1
SCHEMBL4870032 0.69 TEK (0.69) ALDH1A1PARP1ROCK2TEKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
EP-1814552-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS Astex Therapeutics Limited (GB) 2007-08-08 EP disclosed
WO-2006051290-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders CNKSR1, PRKCH, PRKAR2B ALDH1A1 4843/4885PARP1 2645/4885ROCK2 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.